Please check your internet connection and try again.
# Mylotarg (gemtuzumab ozogamicin)
## Overview
Mylotarg is a targeted therapy, specifically a CD33-expressing antibody-drug conjugate, used in the treatment of acute myeloid leukemia (AML). It delivers a cytotoxic agent (calicheamicin derivative) directly to cancer cells expressing CD33.
## Primary Indications
* Acute myeloid leukemia (AML) in adults who are newly diagnosed and ineligible for intensive induction chemotherapy.
* Acute myeloid leukemia (AML) in adults who have relapsed or are refractory to prior AML treatment.
## Adult Dosing
**Newly Diagnosed AML (ineligible for intensive induction chemotherapy):**
* **Day 1:** 3 mg/m² intravenously (IV) once.
* **Day 4:** 3 mg/m² IV once.
* **Day 7:** 2 mg/m² IV once.
* *If achieving a complete remission (CR) or CR with incomplete hematologic recovery (CRi), a second dose of 2 mg/m² IV may be administered approximately 2-4 weeks after the first dose of the second cycle.*
**Relapsed or Refractory AML:**
* **Cycle 1:** 6 mg/m² IV once.
* *If achieving a CR or CRi, a second dose of 3 mg/m² IV may be administered approximately 2-4 weeks after the first dose.*
**Maximum Dose:** Do not exceed a total cumulative dose of 24 mg/m² over the course of treatment.
## Pediatric Dosing
Dosing in pediatric patients is not established.
## Dose Adjustments
* **Hepatotoxicity:** Discontinue or delay treatment based on the severity of liver enzyme elevation or bilirubin increase. Specific dose reductions or discontinuation guidelines are based on AST/ALT levels and bilirubin levels, detailed in the full prescribing information.
* **Thrombocytopenia:** Monitor platelet counts closely. Dose reductions or delays may be necessary if platelet counts fall below specified thresholds.
## Contraindications
* None specifically listed as absolute contraindications in standard labeling, but caution is warranted in patients with severe hepatic impairment or those with a history of hypersensitivity to gemtuzumab ozogamicin or its components.
## Adverse Effects
* **Common:** Febrile neutropenia, nausea, vomiting, diarrhea, stomatitis, headache, rash, fatigue, pyrexia, abdominal pain, hypokalemia, elevated liver enzymes (AST, ALT, bilirubin), thrombocytopenia, anemia, neutropenia.
* **Serious:**
* **Hepatotoxicity:** Including veno-occlusive disease/sinusoidal obstruction syndrome (VOD/SOS), which can be fatal. Signs include jaundice, hepatomegaly, ascites, elevated bilirubin, elevated transaminases, and thrombocytopenia.
* **Infusion Reactions:** Fever, chills, rash, dyspnea.
* **Hemorrhage:** Especially in patients with thrombocytopenia.
* **Myelosuppression:** Leading to neutropenia, thrombocytopenia, and anemia.
## Key Drug Interactions
* **Hepatotoxic Agents:** Concurrent use with other medications known to cause hepatotoxicity may increase the risk of liver damage. Monitor liver function closely.
* **Myelosuppressive Agents:** Concomitant use with other myelosuppressive therapies can potentiate bone marrow suppression.
## Monitoring
* **Liver Function Tests:** Regularly monitor bilirubin, AST, ALT, and alkaline phosphatase before and during treatment.
* **Complete Blood Counts (CBC) with differential and platelet count:** Frequently monitor for neutropenia, thrombocytopenia, and anemia.
* **Signs and Symptoms of Infusion Reactions:** Monitor closely during and after infusion.
* **Signs and Symptoms of VOD/SOS:** Monitor for jaundice, hepatomegaly, ascites, elevated liver enzymes, and thrombocytopenia.
## Clinical Pearls
* Mylotarg is associated with a significant risk of hepatotoxicity, particularly VOD/SOS, which can be dose-limiting and fatal. Close monitoring of liver function and early recognition of VOD/SOS symptoms are critical.
* Thrombocytopenia is common and can increase the risk of bleeding. Prophylactic platelet transfusions may be indicated based on local protocols and clinical assessment.
* Infusion reactions can occur. Premedication may be considered based on institutional guidelines.
* Due to the risk of hepatotoxicity, patients with severe hepatic impairment should be carefully evaluated.
***
*This information is intended for healthcare professionals and is not a substitute for professional medical advice. Always consult the most current prescribing information and local institutional protocols for complete details before making any treatment decisions.*
